DOI QR코드

DOI QR Code

FDG PET or PET/CT in Evaluation of Renal Angiomyolipoma

  • Lin, Chun-Yi (Department of Nuclear Medicine, Show Chwan Memorial Hospital) ;
  • Chen, Hui-Yi (Department of Radiology, China Medical University Hospital) ;
  • Ding, Hueisch-Jy (Department of Nuclear Medicine, E-DA Hospital I-Shou University) ;
  • Yen, Kuo-Yang (Department of Nuclear Medicine and PET Center, China Medical University Hospital) ;
  • Kao, Chia-Hung (Department of Nuclear Medicine and PET Center, China Medical University Hospital)
  • Published : 2013.04.01

Abstract

Objective: Angiomyolipoma is the most common benign kidney tumor. However, literature describing FDG PET findings on renal angiomyolipoma (AML) is limited. This study reports the FDG PET and PET/CT findings of 21 cases of renal AML. Materials and Methods: The study reviews FDG PET and PET/CT images of 21 patients diagnosed with renal AML. The diagnosis is based on the classical appearance of an AML on CT scan with active surveillance for 6 months. The study is focused on the observation of clinical and radiographic features. Results: Six men and 15 women were included in our study. The mean age of the patients was 57.14 ${\pm}$ 9.67 years old. The mean diameter of 21 renal AML on CT scans was 1.76 ${\pm}$ 1.00 cm (Min: 0.6 cm; Max: 4.4 cm). CT scans illustrated renal masses typical of AMLs, and the corresponding FDG PET scans showed minimal FDG activities in the area of the tumors. None of the 21 AMLs showed a maximum standardized uptake value ($SUV_{max}$) greater than 1.98. No statistically significant correlation was present between $SUV_{max}$ and tumor size. Conclusion: Renal AMLs demonstrate very low to low uptake on FDG PET and PET/CT imaging in this study. When a fat-containing tumor in the kidney is found on a CT scan, it is critical to differentiate an AML from a malignant tumor including an RCC, liposarcoma, and Wilms tumor. This study suggests that FDG PET or PET/CT imaging is useful for differentiating a renal AML from a fat-containing malignant tumor.

Keywords

References

  1. Mues, AC, Palacios, JM, Haramis, G, Casazza, C, Badani, K, Gupta, M,Contemporary experience in the management of angiomyolipoma, J Endourol, 24, 1, 1883-1886(2010) https://doi.org/10.1089/end.2010.0223
  2. Kawashima, A, Sandler, CM, Ernst, RD, Tamm, EP, Goldman, SM, Fishman, EK,CT evaluation of renovascular disease, Radiographics, 20, 2, 1321-1340(2000) https://doi.org/10.1148/radiographics.20.5.g00se141321
  3. Bissler, JJ, Kingswood, JC,Renal angiomyolipomata, Kidney Int, 66, 3, 924-934(2004) https://doi.org/10.1111/j.1523-1755.2004.00838.x
  4. Sherman, JL, Hartman, DS, Friedman, AC, Madewell, JE, Davis, CJ, Goldman, SM,Angiomyolipoma: computed tomographic-pathologic correlation of 17 cases, AJR Am J Roentgenol, 137, 4, 1221-1226(1981) https://doi.org/10.2214/ajr.137.6.1221
  5. Halpenny, D, Snow, A, McNeill, G, Torreggiani, WC,The radiological diagnosis and treatment of renal angiomyolipoma-current status, Clin Radiol, 65, 5, 99-108(2010) https://doi.org/10.1016/j.crad.2009.09.014
  6. Kochhar, R, Brown, RK, Wong, CO, Dunnick, NR, Frey, KA, Manoharan, P,Role of FDG PET/CT in imaging of renal lesions, J Med Imaging Radiat Oncol, 54, 6, 347-357(2010) https://doi.org/10.1111/j.1754-9485.2010.02181.x
  7. Zapardiel, I, Delafuente-Valero, J, Bajo-Arenas, JM,Renal angiomyolipoma during pregnancy: review of the literature, Gynecol Obstet Invest, 72, 7, 217-219(2011) https://doi.org/10.1159/000329328
  8. Lhommel, R, Annet, L, Bol, A, Gigot, JF, Sempoux, C, Mathieu, I,PET scan with 11C-acetate for the imaging of liver masses: report of a false positive case, Eur J Nucl Med Mol Imaging, 32, 8, 629(2005) https://doi.org/10.1007/s00259-004-1698-3
  9. Ho, CL, Chan, WK, Chen, S, Leung, YL, Cheng, TK,Education and Imaging. Hepatobiliary and pancreatic: imaging for hepatic angiomyolipoma, J Gastroenterol Hepatol, 25, 9, 1589(2010) https://doi.org/10.1111/j.1440-1746.2010.06475.x
  10. Arnold, RT, Myers, DT,Visualization of renal angiomyolipoma on F-18 FDG PET/CT, Clin Nucl Med, 34, 10, 539-540(2009) https://doi.org/10.1097/RLU.0b013e3181abb6cf
  11. Lemaitre, L, Claudon, M, Dubrulle, F, Mazeman, E,Imaging of angiomyolipomas, Semin Ultrasound CT MR, 18, 11, 100-114(1997) https://doi.org/10.1016/S0887-2171(97)90054-8
  12. Davenport, MS, Neville, AM, Ellis, JH, Cohan, RH, Chaudhry, HS, Leder, RA,Diagnosis of renal angiomyolipoma with hounsfield unit thresholds: effect of size of region of interest and nephrographic phase imaging, Radiology, 260, 12, 158-165(2011) https://doi.org/10.1148/radiol.11102476
  13. Namura, K, Minamimoto, R, Yao, M, Makiyama, K, Murakami, T, Sano, F,Impact of maximum standardized uptake value (SUV) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report, BMC Cancer, 10, 13, 667(2010) https://doi.org/10.1186/1471-2407-10-667
  14. Jemal, A, Siegel, R, Ward, E, Murray, T, Xu, J, Thun, MJ,Cancer statistics, 2007, CA Cancer J Clin, 57, 14, 43-66(2007) https://doi.org/10.3322/canjclin.57.1.43
  15. Bachor, R, Kotzerke, J, Gottfried, HW, Brandle, E, Reske, SN, Hautmann, R,[Positron emission tomography in diagnosis of renal cell carcinoma], Urologe A, 35, 15, 146-150(1996)
  16. Kang, DE, White, RL, Zuger, JH, Sasser, HC, Teigland, CM,Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma, J Urol, 171, 16, 1806-1809(2004) https://doi.org/10.1097/01.ju.0000120241.50061.e4
  17. Aide, N, Cappele, O, Bottet, P, Bensadoun, H, Regeasse, A, Comoz, F,Efficiency of [(18)F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT, Eur J Nucl Med Mol Imaging, 30, 17, 1236-1245(2003) https://doi.org/10.1007/s00259-003-1211-4
  18. Martinez de Llano, SR, Delgado-Bolton, RC, Jimenez-Vicioso, A, Perez-Castejon, MJ, Carreras Delgado, JL, Ramos, E,[Meta-analysis of the diagnostic performance of 18F-FDG PET in renal cell carcinoma], Rev Esp Med Nucl, 26, 18, 19-29(2007) https://doi.org/10.1157/13097378
  19. Edinger, AL, Linardic, CM, Chiang, GG, Thompson, CB, Abraham, RT,Differential effects of rapamycin on mammalian target of rapamycin signaling functions in mammalian cells, Cancer Res, 63, 19, 8451-8460(2003)
  20. Jiang, X, Kenerson, H, Aicher, L, Miyaoka, R, Eary, J, Bissler, J,The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake, Am J Pathol, 172, 20, 1748-1756(2008) https://doi.org/10.2353/ajpath.2008.070958

Cited by

  1. WARM N COLD: malignant and benign renal tumors in children vol.21, pp.3, 2014, https://doi.org/10.1007/s10140-014-1202-8
  2. Malignant Renal Epithelioid Angiomyolipoma With Liver Metastasis After Resection: A Case Report With Multimodality Imaging and Review of the Literature vol.38, pp.4, 2014, https://doi.org/10.1097/rct.0000000000000101
  3. Diagnostic Challenges of Kidney Cancer: A Systematic Review of the Role of Positron Emission Tomography-Computerized Tomography vol.196, pp.3, 2013, https://doi.org/10.1016/j.juro.2016.02.2992
  4. Author reply vol.27, pp.2, 2013, https://doi.org/10.4103/ijri.ijri_506_16
  5. Renal angiomyolipoma without visible fat: Can we make the diagnosis using CT and MRI? vol.28, pp.2, 2013, https://doi.org/10.1007/s00330-017-4988-4
  6. Mammalian target of rapamycin inhibitor and transarterial embolization for treatment of tuberous sclerosis complex patients with renal angiomyolipoma vol.n, pp.None, 2013, https://doi.org/10.4103/uros.uros_19_17
  7. Exploring serum metabolic markers for the discrimination of ccRCC from renal angiomyolipoma by metabolomics vol.14, pp.8, 2013, https://doi.org/10.2217/bmm-2019-0215